1. NAD+ reverses deficient OCR in a cell-based model of amyloid-β toxicity and as well in AD-Tg mice reversed by NMN2. Decreased full-length mutant human APP levels in the brain of NMN-treated transgenic mice. The gene discussed is APP; the disease is Alzheimer disease.